Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
Co-characterized GH-axis pairing (Tesamorelin + Ipamorelin)
Overview
The Tesamorelin + Ipamorelin pairing combines a GHRH-receptor agonist (Tesamorelin) with a GHSR / ghrelin-receptor agonist (Ipamorelin) — the same dual-pathway architecture as the canonical CJC-1295 + Ipamorelin pairing, with Tesamorelin substituted on the GHRH arm. The two receptors converge on somatotroph signalling, which is the reason the pairing is studied together in somatotropic-axis research. The material is referenced here as a characterized pairing of two standards, not for any GH-secretion outcome. Consistent with Lyochem's methodology for multi-component systems, the two components are characterized on their own analytical packets rather than presented as a blend whose per-component data is obscured: Tesamorelin and Ipamorelin are each supplied as separately characterized lots — RP-HPLC purity (gradient method, UV 214 nm), ESI-MS identity, sequence confirmation by LC-MS/MS on request, counter-ion content, and water content by Karl Fischer — so each can be confirmed against its own standard before a lab prepares the combination in-protocol. The components carry individual CAS numbers rather than a single registered identifier for the pairing; confirm each component's API by COA / label before use. This is reference-grade research material, distinct from compounding-scale API supply.
Applications & buyer fit
GH-axis peptides ship to research labs studying somatotropic-pathway pharmacology, IGF-axis signalling, and pulse vs. sustained-elevation GH biology. Buyers qualifying a new source typically request sequence verification on the first lot, the counter-ion form (acetate by default), and stability data at −20 °C. Blends — the CJC-1295 + Ipamorelin co-formulated lot is the canonical example — are co-lyophilised rather than solution-mixed so the ratio is locked at the lyophilisation step.
Academic Laboratories
Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.
Biotech R&D Groups
Preclinical biotech and pharmaceutical discovery teams sourcing characterized peptides for receptor-pharmacology, screening, and method-development campaigns.
Every release ships with its own batch-specific CoA — identity, purity, and the analytical scope agreed at quote stage, tied to the exact lot you receive.
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.
Specifications
Documentation available on request
Regulatory note
Components carry individual CAS numbers — confirm each component's API identity by batch COA / label before use. Lyochem supplies this pairing strictly for Research Use Only; buyers are responsible for verifying ingredient eligibility in their destination market.
Frequently asked questions
Both pair a GHRH-receptor agonist with the GHSR agonist Ipamorelin to probe the two converging arms of somatotroph signalling; the difference is the GHRH-arm molecule. Tesamorelin and CJC-1295 (no-DAC) differ in their pharmacokinetic profiles, so the two pairings are studied as related but non-identical dual-pathway reference systems. Lyochem supplies each component as an independently characterized lot in either pairing.
No. Tesamorelin and Ipamorelin are supplied as separate characterized lots, each with its own analytical packet, so a lab can confirm the identity and purity of each before preparing the combination in-protocol at its chosen ratio. A pre-mixed vial would obscure the per-component analytical data a citable methods section needs.
It is a combination of two distinct molecules, each with its own CAS Registry Number, rather than a single chemical entity. Identity is established at the component level on each lot COA; buyers should confirm each component's API by COA or label rather than relying on the pairing name.
Related peptides
29-mer
GHRH analog · approved for HIV-associated lipodystrophy
Ghrelin / GHSR pathway GH-release peptide
GH-axis blend (CJC-1295 no DAC + Ipamorelin)